Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab

BACKGROUND: Ramucirumab, the human immunoglobulin G1 monoclonal antibody receptor antagonist of vascular endothelial growth factor receptor 2, has been approved for treating gastric/gastroesophageal junction, non-small-cell lung, and metastatic colorectal cancers. With the completion of six global,...

Descripción completa

Detalles Bibliográficos
Autores principales: Arnold, D, Fuchs, C S, Tabernero, J, Ohtsu, A, Zhu, A X, Garon, E B, Mackey, J R, Paz-Ares, L, Baron, A D, Okusaka, T, Yoshino, T, Yoon, H H, Das, M, Ferry, D, Zhang, Y, Lin, Y, Binder, P, Sashegyi, A, Chau, I
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5834052/
https://www.ncbi.nlm.nih.gov/pubmed/28950290
http://dx.doi.org/10.1093/annonc/mdx514

Ejemplares similares

Ejemplares similares